<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01641393</url>
  </required_header>
  <id_info>
    <org_study_id>PR-005</org_study_id>
    <secondary_id>2009-012842-21</secondary_id>
    <nct_id>NCT01641393</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.</brief_title>
  <official_title>A Randomised, Double-Blind, Active-Controlled, Two-Treatment, Crossover, Multinational, Multicentre Study to Compare Two Pancreatic Enzyme Products in the Treatment of Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Forest Laboratories</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to further evaluate the safety and efficacy of EUR-1008 as
      compared to Kreon® in the treatment of exocrine pancreatic insufficiency associated with
      Cystic Fibrosis in subjects 12 years of age and older.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coefficient of Fat Absorption over 72 hours (CFA-72h)</measure>
    <time_frame>72 hours</time_frame>
    <description>During the last 72 hours of each treatment period, the CFA-72h will be calculated using fat intake data from the diet and fat excretion data from stools. Fat intake will be calculated by the dietician in collaboration with the study investigator using a validated tool.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>58 days.</time_frame>
    <description>Body weight at baseline (Visit 2 [Day 0]) and at the end of each treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coefficient of nitrogen absorption</measure>
    <time_frame>72 hours</time_frame>
    <description>Coefficient of nitrogen absorption at the end of each treatment period as assessed by a specialised central laboratory by means of Dumas combustion method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Control of signs and symptoms of EPI</measure>
    <time_frame>2- 14 day periods</time_frame>
    <description>Control of signs and symptoms of EPI (as recorded in subject diaries). The following will be captured:
Stools frequency (number/day)
Stools consistency (hard, formed/normal; soft, watery, overt diarrhoea)
Fat or grease visible in stools (Yes/No)
Abdominal pain (mild, moderate, severe)
Bloating (mild, moderate, severe)
Flatulence (mild, moderate, severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on overall health, daily life, perceived well-being, and symptoms</measure>
    <time_frame>58 days</time_frame>
    <description>Impact on overall health, daily life, perceived well-being, and symptoms evaluated using the CFQ (administered by designated study personnel prior to randomisation and at the end of each treatment period).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol, calculated LDL-C, HDL-C</measure>
    <time_frame>58 days</time_frame>
    <description>Total cholesterol, calculated LDL-C, HDL-C (sampling performed prior to randomisation and at the end of each treatment period).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Emergent Adverse Events</measure>
    <time_frame>78 days</time_frame>
    <description>Frequency, duration, and severity of treatment-emergent adverse events (TEAEs);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard safety laboratory tests</measure>
    <time_frame>58 days</time_frame>
    <description>Standard safety laboratory tests, analysed by central laboratory:
Haematology: red blood cell count, haemoglobin, haematocrit, total leukocytes with diff count, and platelets
Serum biochemistry: alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total protein, albumin, total bilirubin, direct and indirect bilirubin, blood urea nitrogen, uric acid, creatinine, fasting plasma glucose, fasting cholesterol evaluations (total cholesterol, LDL-C, HDL-C, and triglycerides), fat-soluble vitamins (A, D, and E) and serum electrolytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>78 days</time_frame>
    <description>Vital signs including blood pressure, heart rate, respirations and body temperature.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat-soluble vitamins A, D, and E</measure>
    <time_frame>58 days</time_frame>
    <description>Fat-soluble vitamins A, D, and E (sampling performed prior to randomisation and at the end of each treatment period).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Exocrine Pancreatic Insufficiency: Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>EUR-1008 then Kreon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EUR-1008 during Treatment Period 1 (29 days ±2 days) and
Kreon during Treatment Period 2 (29 days ±2 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kreon then EUR-1008</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Kreon during Treatment Period 1 (29 days ±2 days) and
EUR-1008 during Treatment Period 2 (29 days ±2 days).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EUR-1008 25,000 Units</intervention_name>
    <description>EUR-1008 25,000 Units is a PEP with pancreas powder as the active ingredient.18 Pancreas powder contains various enzymes having proteolytic, lipolytic, and amylolytic activity. Each capsule contains approximately 25,000 Ph. Eur. lipase units. EUR-1008 25,000 consists of orally administered capsules containing enteric-coated beads.</description>
    <arm_group_label>EUR-1008 then Kreon</arm_group_label>
    <arm_group_label>Kreon then EUR-1008</arm_group_label>
    <other_name>Zenpep</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kreon 25,000 Units</intervention_name>
    <description>Kreon 25,000 is a PEP consisting of porcine-derived pancreatic enzymes.18 Each capsule contains approximately 25,000 Ph. Eur. lipase units. Kreon 25,000 consists of orally administered capsules containing enteric-coated spheres.</description>
    <arm_group_label>EUR-1008 then Kreon</arm_group_label>
    <arm_group_label>Kreon then EUR-1008</arm_group_label>
    <other_name>Kreon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Definitive diagnosis of CF based on the following:

               -  One clinical feature consistent with CF and

               -  Either a genotype with 2 identifiable mutations known to cause CF or a sweat
                  chloride concentration &gt;60 mEq/L by pilocarpine iontophoresis

          2. Pancreatic insufficiency documented by a monoclonal faecal elastase (FE) 100 μg/g
             stool at screening (test results within the previous 12 months are acceptable)

          3. Currently receiving pancreatic enzyme replacement therapy

          4. Adequate nutritional status based on the following: body mass index (BMI) &gt;19 kg/m2 in
             adult subjects or a BMI percentile 10th percentile for age in adolescent (12 to 17
             years age group) subjects

          5. Are clinically stable with no evidence of concomitant illness or acute upper or lower
             respiratory tract infection that requires antibiotics during the 7-day interval prior
             to screening and preceding entry into this clinical study

        Exclusion Criteria:

          1. Age &lt;12 years

          2. Known contraindication, hypersensitivity, or intolerance to pork or other porcine PEPs

          3. Current uncontrolled diabetes mellitus

          4. History of solid organ transplantation

          5. History of surgery affecting the bowel function and weight gain
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Taylor, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheffield Children's Hospital, The Academic Unit of Child Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Antwerp - Universitair Ziekenhuis Antwerpen (UZA)</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent, Centrum voor Mucoviscidose</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Paediatric Diseases at UMHAT Dr Georgi Stranski</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Genetic and Paediatric Diseases at UMHAT Sveti Georgi</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialized Hospital for Active Treatment of Pulmological and Phtisiatric Disease</name>
      <address>
        <city>Ruse</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Clinic for Specialized Pediatric Clinic at MHAT Sveta Marina</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nouvel Hôpital Civil</name>
      <address>
        <city>Strasbourg Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruhr-Universitaet Bochum - St. Josef Hospital</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Carl Gustav Carus an der TU Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitaetsklinikum Essen gGmbH</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen Zentrum f.Kinderheilkunde Klinik f.Kinderheilkunde III</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Jena, Klinik fur Kinder und Jugendmedizin</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik Innenstadt</name>
      <address>
        <city>Muenchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik für Kinder- und Jugendmedizin Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria, Ospedali Riuniti, Ospedale Pediatrico G. Salesi</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedale Policlinico di Bari</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Catania</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Policlinico G. Martino, Gastroenterologia Pediatrica E Fibrosi Cistica</name>
      <address>
        <city>Contesse -Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Federico II of Naples, Pediatrics Department</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica di Malattie dell'Apparato Respiratorio</name>
      <address>
        <city>Orbassano (Torino)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Azienda Ospedaliera Universitaria</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita degli Studi di Roma La Sapienza, Azienda Policlinico Umberto I, Dipartimento di Pediatria, Centro Fibrosi Cistica Regione Lazio</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bambino Gesu Hospital, Cystic Fibrosis Unit</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Infantile Regina Margherita</name>
      <address>
        <city>Turin</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrata, Centro Fibrosi Cistica-Ospedale Civile Maggiore</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczny Zespot Opieki Zdrowotnej nad Matka i Dzieckiem Poradnia Leczenia Mukowiscydozy</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Pulmonologii i Alergologii w Karpaczu</name>
      <address>
        <city>Karpacz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny im Kopernika</name>
      <address>
        <city>Lodzi</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ALERGOTEST s.c Specjalistyczne Centrum Medyczne</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny im Karola Jonschera</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Sanatorium Cassia Villa Medica</name>
      <address>
        <city>Rabka Zdrój</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Podkarpacki Osrodek Pulmonologii i Alergologii</name>
      <address>
        <city>Rzeszow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Zdrowia Matki, Dziecka i Mlodziezy</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRMED Irena Wojciechowska</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liverpool Heart and Chest Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheffield Children's Hospital, The Academic Unit of Child Health</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2012</study_first_submitted>
  <study_first_submitted_qc>July 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2012</study_first_posted>
  <last_update_submitted>March 13, 2014</last_update_submitted>
  <last_update_submitted_qc>March 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Exocrine Pancreatic Insufficiency</keyword>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Pancreatic Insufficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

